Raptor Pharmaceuticals Provides Update on Targeting...(ns and Methodsfor Modulating Blood-Brain...),Health

Date:11/6/2008

ns and Methods for Modulating Blood-Brain Barrier Transport." Allowed claims concern methods for identifying molecules that cross from blood to brain through a specific receptor-dependent process. The patent is designed to provide some protection in Japan to Raptor's NeuroTrans(TM) platform currently in development to potentially transport therapeutics from the blood to the brain.

Dr. Christopher M. Starr, President and CEO of Raptor, commented, "The progress we've made with our RAP-based development programs adds another layer of depth to our development pipeline. We believe that the proposed research with Brigham and Women's Hospital is likely to add significant value to our RAP-based approach and the Japanese patent will aid in protecting our emerging NeuroTrans(TM) platform. Over the last year we have initiated three mid-stage clinical studies with in-licensed compounds while we advanced our RAP-based preclinical drug candidates and drug-targeting platforms. We have what we believe is a promising suite of clinical-stage product candidates and preclinical drug-targeting platforms that is designed to address a wide and growing range of unmet medical needs."

About Raptor Pharmaceuticals Corp.

Raptor Pharmaceuticals Corp. ("Raptor") is a development-stage biopharmaceutical company focused on improving drug targeting to expand the reach and benefit of existing therapeutics into underserved patient populations. The Company is currently running clinical trials in patients with aldehyde dehydrogenase ("ALDH2") deficiency, nephropathic cystinosis and non-alcoholic steatohepatitis ("NASH"). Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins to that are designed to target cancer, neurodegenerative disorders and infectious diseases.

For additional information, please visit '/>"/>

SOURCE Raptor Pharmaceuticals Corp. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine technology :

1. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
2. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
3. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
4. Raptor Pharmaceuticals Provides Update of Product Programs
5. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
6. Mpex Pharmaceuticals Announces Initiation of a Phase 2 Clinical Trial of Aerosol MP-376 in COPD
7. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
8. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
9. Sequoia Pharmaceuticals Presents In Vitro and First-in-Human Data Supporting Further Development of SPI-256, a Novel Investigational Protease Inhibitor
10. Minster Pharmaceuticals Plc Announces Positive Results from Phase II Trial of Migraine with Aura
11. Addrenex Pharmaceuticals Initiates Phase 2 Trial on Its Novel Hypertension Drug, ADX415